John J. O'Shea

He did additional postdoctoral work in the Cell Biology and Metabolism Branch in the National Institute of Child Health and Human Development.

A major focus of the Branch is the study of receptor-mediated signal transduction and how these events link to the regulation of genes involved in inflammatory responses.

His area of scientific interest is cytokine signal transduction, dissecting the role of Jaks and Stats family transcription in immunoregulation.

More recently, O'Shea's laboratory has employed deep sequencing to understand the epigenetic regulation of T cell differentiation and the role of STATs in these processes.

O'Shea collaborated with colleagues at Pfizer including Paul Changelian to develop the Janus kinase inhibitor tofacitinib.